Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.00245171 | 0.474139 | 0.661405 | |
Onchocerca volvulus | 0.00290482 | 0.667886 | 1 | |
Brugia malayi | SEA domain containing protein | 0.00245171 | 0.474139 | 0.661405 |
Echinococcus granulosus | tissue type plasminogen activator | 0.00156661 | 0.095678 | 0.5 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.00245171 | 0.474139 | 0.661405 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.00156661 | 0.095678 | 0.5 |
Brugia malayi | Muscle positioning protein 4 | 0.00290482 | 0.667886 | 1 |
Schistosoma mansoni | matrix metallopeptidase-9 (M10 family) | 0.00368153 | 1 | 1 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.00156661 | 0.095678 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00156661 | 0.095678 | 0.095678 |
Onchocerca volvulus | 0.00245171 | 0.474139 | 0.661405 | |
Onchocerca volvulus | 0.00245171 | 0.474139 | 0.661405 | |
Onchocerca volvulus | 0.00245171 | 0.474139 | 0.661405 | |
Toxoplasma gondii | kringle domain-containing protein | 0.00156661 | 0.095678 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.00173969 | 0.169687 | 0.169687 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.00156661 | 0.095678 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.00156661 | 0.095678 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00290482 | 0.667886 | 1 |
Leishmania major | hypothetical protein, conserved | 0.00156661 | 0.095678 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00245171 | 0.474139 | 0.474139 |
Loa Loa (eye worm) | hypothetical protein | 0.00245171 | 0.474139 | 0.661405 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | 24568587 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.